Acasti Pharma unveils proposal to buy Grace Therapeutics and its portfolio of drug candidates in all-stock deal
Acasti will acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple preclinical stage assets, supported by an intellectual property portfolio of more than 40 granted and pending patents
Both companies' boards have approved the deal thus far, as have Grace stockholders
Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has announced a definitive agreement to acquire Grace Therapeutics Inc, a privately-held biopharmaceutical company developing drug delivery technologies for the treatment of rare and orphan diseases.
The deal would have Acasti acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple preclinical stage assets, supported by an intellectual property portfolio of more than 40 granted and pending patents globally. Both companies' boards have approved the deal thus far, as have Grace stockholders.